The grocery giant attributed its Q2 performance to aggressive cost savings and profitable e-commerce growth, which offset a challenging top-line environment. However, it lowered its full-year identical sales outlook from previous expectations, reflecting first-half results and anticipated Q4 pharmacy sales headwinds from the Inflation Reduction Act. The company also resumed share repurchases, totaling approximately $1.2 billion in the first half, with plans to complete the remaining $800 million authorization by year-end.